The BAT is employed alongside clinical observations, and biological parameters, to monitor and potentially predict safe administration of IgE immunotherapies.15 For SF-25 IgE, further ex vivo BAT assays using different SLC3A2+ cancer patient cohorts will confirm lack of basophil activation and provide confidence in future safe administration to humans. This evidence concerns the gene SLC3A2 and cancer.